Glympse Bio
Jul 16, 2020
Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update
Orchard licenses the gene therapy technology from GlaxoSmithKline Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
